Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus).

Ross C, Salmon AB, Strong R, Fernandez E, Javors M, Richardson A, Tardif S · 2015 · Aging · Atlas ID ROS2015

What this study shows

Long-term oral encapsulated rapamycin in marmosets had only minor metabolic consequences. Body weight was unchanged overall and fat mass fell only slightly over the first few months. Daily activity counts, blood lipids and glucose metabolism, including oral glucose tolerance, did not change significantly, and adipose tissue showed no difference in metabolic-marker gene expression. In liver, G6Pase activity was suppressed while PCK and GPI activity increased. Boundary: marmoset, oral rapamycin, metabolic endpoints only; the abstract gives neither the dose nor group sizes, and no lifespan result is reported.

Abstract

ShowHide

Rapamycin has been shown to extend lifespan in rodent models, but the effects on metabolic health and function have been widely debated in both clinical and translational trials. Prior to rapamycin being used as a treatment to extend both lifespan and healthspan in the human population, it is vital to assess the side effects of the treatment on metabolic pathways in animal model systems, including a closely related non-human primate model.

Read the full abstract on PubMed →

At a glance

Evidence type	A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Common marmoset (Callithrix jacchus), long-term oral encapsulated rapamycin, metabolic phenotyping); the code names the system studied -- animal work can be rigorous and still not be human data.
Study type	4 - Animal Study
Model system	Common marmoset (Callithrix jacchus), long-term oral encapsulated rapamycin, metabolic phenotyping
Journal	Aging
Year	2015
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.18632/aging.100843 · PMID 26568298 · Free full text (PMC4694066)

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Long-term oral encapsulated rapamycin
Target	Systemic metabolism (body composition, glucose handling, liver gluconeogenic enzymes)
Model	Common marmoset (Callithrix jacchus)
Effect	Only minor metabolic consequences: no change in weight, lipids or glucose tolerance; small early fat-mass decrease; altered liver G6Pase, PCK and GPI activity

In the Atlas

Cite this paper

ShowHide

Ross, C., Salmon, A. B., Strong, R., Fernandez, E., Javors, M., Richardson, A., & Tardif, S. (2015). Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging. https://doi.org/10.18632/aging.100843

@article{ROS2015,
  author       = {Ross, C. and Salmon, A. B. and Strong, R. and Fernandez, E. and Javors, M. and Richardson, A. and Tardif, S.},
  title        = {{Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)}},
  journal      = {Aging},
  year         = {2015},
  doi          = {10.18632/aging.100843},
  note         = {PMID: 26568298},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record ROS2015) [Data set]. https://mtor-atlas.org/study/ROS2015/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_ROS2015,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record ROS2015},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/ROS2015/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?